Relapse-specific mutations in phosphoribosyl pyrophosphate synthetase 1 (PRPS1), a rate-limiting purine biosynthesis enzyme, confer significant drug resistances to combination chemotherapy in acute lymphoblastic leukemia (ALL). It is of particular interest to identify drugs to overcome these resistances. In this study, we found that PRPS1 mutant ALL cells specifically showed more chemosensitivity to 5-Fluorouracil (5-FU) than control cells, attributed to increased apoptosis of PRPS1 mutant cells by 5-FU. Mechanistically, PRPS1 mutants increase the level of intracellular phosphoribosyl pyrophosphate (PRPP), which causes the apt conversion of 5-FU to FUMP and FUTP in Reh cells, to promote 5-FU-induced DNA damage and apoptosis. Our study not only provides mechanistic rationale for re-targeting drug resistant cells in ALL, but also implicates that ALL patients who harbor relapse-specific mutations of PRPS1 might benefit from 5-FU-based chemotherapy in clinical settings.
| INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, accounting for more than 25% of all childhood cancers. 1 Although risk-stratified combination chemotherapy has improved the cure rate of ALL patients, relapsed ALL remains a leading cause of mortality among all childhood malignancies. 2 The thiopurines 6-thioguanine (6-TG) and 6-mercaptopurine (6-MP) are key drugs in maintenance therapy which will continue for the next two to two-anda-half years after initial remission, and both are prodrugs converted by the purine salvage pathway to cytotoxic thioguanine nucleotides. 3 Therefore, dysfunction of the enzymes involved in purine metabolism has been associated with the ALL recurrence. 4 We previously identified multiple relapse-specific mutations in phosphoribosyl pyrophosphate synthetase 1 gene (PRPS1), which encodes a rate-limiting purine biosynthesis enzyme, in 24/358 (6.7%) relapsed childhood B-ALL samples. Among these mutations, the encoding residues A190
and S103 are hotspot mutation sites presented in 11/24 and 4/24 patients, respectively. Mechanistically, negative feedback-defective PRPS1 mutants result in constitutive activation of purine biosynthesis and accumulation of purine nucleotides in cells. Increased hypoxanthine (HX) competitively inhibits activation of 6-MP and 6-TG, leading to thiopurine resistance and tumor relapse. 5 In addition to 6-MP and 6-TG, PRPS1 mutant cells also confer slight resistance to other commonly used ALL chemotherapeutic drugs, such as methotrexate (MTX) and cytosine arabinoside (Ara-C). However, no drug has been shown to overcome relapse-specific PRPS1 mutant-conferred drug resistance and to directly target PRPS1 mutant cells.
5-Fluorouracil (5-FU) as an antimetabolite drug is widely used in
the treatment of a range of cancers. broken down by DPD in the liver. 9 Numerous studies have shown that expression levels of TS, DPD and OPRT could affect tumor cell sensitivity to 5-FU. [10] [11] [12] [13] [14] However, it remains unknown whether 5-FU has effective role in treating ALL, and especially targeting PRPS1 mutant ALL cells.
In this study, we demonstrated that 5-FU can specifically sensitize ALL cells with PRPS1 mutants (A109T and S103T) by increasing DNA damage and apoptosis. We also found that 5-FU is more 
| Cell culture
The human lymphoblastic leukemia Reh, Jurkat and Nalm-6 cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 100 U/ mL penicillin G and 100 μg/mL streptomycin. HCT116 cells were cultured in McCoy's 5a Medium supplemented with 10% FBS, 100 U/mL penicillin G and 100 μg/mL streptomycin. SW480 and HEK293T cells were cultured in Dulbecco's Modified Eagle Medium supplemented with 10% FBS, 100 U/mL penicillin G and 100 μg/mL streptomycin.
All cells were incubated at 37°C under 5% CO 2 . Cell lines were regularly authenticated and tested for mycoplasma contamination.
| Lentivirus production and infection
Lentivirus expression plasmids of wild-type and mutant PRPS1 were described in our previous report. 5 Lentivirus production was performed as described previously. 5 Briefly, lentiviral constructs were packaged in plasmids PSPAX2 and PMD2G and transfected into HEK293T cells using FuGENE-6 to produce viruses. Supernatant was used to infect Reh cells after concentration. GFP-positive cells were sorted in a MofloXDP. 
| Metabolites extraction and LC-MS

| Cell viability assay
Cell viability and IC50 was determined as described previously. 
| Cell survival
Cells were plated in 96-well plates (15 000 cells per well) with three replicates. Cell viability was measured through CellTiter-Glo reagents at different time points (0, 24, 48 and 72 hours) after dosing. Relative proliferation rate at different time points was calculated with 0 hour as control.
| Annexin V/propidium iodide (PI) analysis
Apoptosis analyzed by Annexin V/PI was described previously. 5 Briefly, cells were plated in 24-well plates (1 × 10 6 cells/1 mL medium) and treated with 1.5 μg/mL 5-FU for 72 hours. Apoptosis was measured by staining with annexin V-APC and PI followed by flow cytometry.
| Western blot analysis
Western blot was performed as described previously. Hangzhou, China, 1:1000 dilution), Actin (HuaAn Biotechnology, 1:5000 dilution), and GAPDH (HuaAn Biotechnology, 1:5000 dilution). Immunoblots were analyzed using the Odyssey system.
| Gene knockdown
Gene knockdown was performed as described previously. 5 Briefly, clustered regularly interspaced short palindromic repeats (CRISPR)/ Cas9 system was used to knock out genes in Reh cells accordingly.
CRISPRs were designed based on information available at http:// crispr.mit.edu and cloned into lentiCRISPR/Cas9 vector by following the Zhang laboratory's protocol. The sequence targeted by PRPS1, TK and OPRT CRISPR are 5′-GAAATTGGTGAAAGTGTACG-3′;
5′-CACCGGAACAGATAACTGTAGCCAA-3′; 5′-CACCGCAAGACCC GGGGGCAGATCC-3′, respectively. The cells were infected with lentivirus and selected by using puromycin. Mixed cells were subjected to further experiments.
| Mouse Models and Chemotherapy
Xenograft models of human ALL were established in B-NDG (NOD-
WT and mutant cell transplantations were performed by tail vein injection (1 × 10 7 cells for each) in mice aged 5 weeks. After transplantation, the mice were monitored to detect the appearance of leukemic symptoms, such as weight loss, hunch-back and decreased activity. Then leukemic mice were treated with 5-FU (100 mg/kg, intraperitoneally) for 3 days. After chemotherapy, the mice were sacrificed for isolating bone marrow cells from tibias. GFP + cells were analyzed by flow cytometry.
| Statistical analysis
All data were analyzed by GraphPad Prism 6.0 software. Comparison between two groups was performed using t test. Data for survival curve were analyzed via two-way ANOVA (multiple comparison-analysis of different treatment groups at the same time). Data were shown as means ± SD.
| RESULTS
| 5-FU sensitizes PRPS1 mutant ALL cells
To screen chemotherapeutic drugs which can overcome PRPS1 mutant-driven drug resistance, we performed cell viability assay by measuring half maximal inhibitory concentration (IC50) to analyze the effects of PRPS1 wild-type (WT) and PRPS1 mutants (A190T and S103T) in response to multiple chemotherapeutic drugs in Reh human ALL cell line. As shown in Figure 1A -D, the viability of Reh cells harboring PRPS1 mutants dramatically increased after treatment with both 6-MP and 6-TG, whereas the cells harboring PRPS1 WT
showed slight resistance to 6-MP and 6-TG, consistent with our previous findings that relapse-specific PRPS1 mutations confer thiopurine resistance. 5 Meanwhile, these cells had a minor resistance to doxorubicin (DXR) but no significant sensitivity to vincristine (VCR) ( Figure 1E and F) , both of drugs are also commonly used in ALL treatment. In addition, we also assessed the chemosensitivity of Figure 1G ), despite that none of these cells showed significant chemosensitivity to HU and cisplatin compared to the control cells ( Figure 1H and I) . Similarly, we also found PRPS1 mutants showed more chemosensitivity to 5-FU than PRPS1
WT did in other two ALL cell lines, Jurkat and Nalm6 ( Figure 1A-D) .
Furthermore, we obtained the primary ALL cells from the patients to confirm this effect. As shown in Figure 1J , the relapse cells (ALL-190R), which harbored PRPS1 S103R mutation, were more sensitive to 5-FU action than diagnosis samples (ALL-190D). Additionally, the results from xenograft mice models also demonstrated that 5-FU had better chemotherapeutic effect in vivo against PRPS1 mutant cells rather than PRPS1 WT cells ( Figure 1K ). Taken together, these results indicated that 5-FU could sensitize PRPS1 mutant ALL cells.
| 5-FU promotes the apoptosis of PRPS1 mutant ALL cells
We further showed that the proliferation rate of PRPS1 mutant ALL Percentage of apoptotic cells was detected at 72 hours after treatment with 1.5 μg/mL 5-FU by annexin-V/PI staining assay. ***P < 0.001, two-tailed Student's t tests. (C-E) 5-FU caused enhancement of DNA damage response and apoptosis in PRPS1 mutant cells compared to that in PRPS1 WT and control cells. Cells were harvested at 48 hours after treatment with 1.5 μg/mL 5-FU and the sample wasanalyzed by Western blot. Quantification of protein level was conducted by using ImageJ software. *P < 0.05, **P < 0.01, and ****P < 0.0001, two-tailed Student's t tests. (F) DDR marker yH2AX was upregulated in PRPS1 mutant cells as detected byimmunofluorescence assay at 48 hours after treatment with 1.5 μg/mL 5-FU sensitivity to 5-FU. As shown in Figure 5E and F, extra adding of R-5-P or PRPP in culture medium could enhance Reh cell sensitivity to 5-FU. Otherwise, the proliferation rate of Reh cells was significantly decreased with the treatment of R-5-P or PRPP ( Figure S2D and E).
We further knocked down PRPS1 to reduce the levels of intracellular PRPP in Reh cells ( Figure 5G and Figure S2C ). The data from cell 
| DISCUSSION
Uncontrolled cell proliferation, as one of the characteristics of tumor cells, requires abundant nucleotides to support DNA and RNA synthesis. 17 PRPS1, a rate-limiting enzyme for nucleotide biosynthesis,
plays an important role in maintaining intracellular nucleotide level and cell growth. 18 Recent studies showed that expression level of PRPS1 is critical for tumorigenesis and clinical prognosis of cancer patients, based on the findings that both mRNA level and protein level of PRPS1 are up-regulated in human colorectal cancer samples, and patients with high PRPS1 expression show poor prognosis. 19 Furthermore, reduced expression of PRPS1 impairs tumor cell proliferation. In contrast, PRPS1 also remarkably affects cell proliferation and colony formation in glioblastoma stem cells. 20 We previously identified relapse-specific PRPS1 mutations in childhood B-ALL samples, and uncovered that ALL individuals who harbored PRPS1 mutations relapsed early during treatment. Mechanistic studies further revealed that drug-resistant PRPS1 mutants caused increased purine nucleotide biosynthesis by a mechanism of gain-of-function, and thus, elevated hypoxanthine competitively inhibits thiopurine conversion, conferring resistance to thiopurines. 5 In despite of that, lometrexol, an inhibitor of de novo purine synthesis, can abrogate PRPS1 mutant-driven thiopurine resistance. FUMP by inhibiting purine biosynthesis. 24 However, whether PRPP has any role in 5-FU resistance is still incompletely clear until now.
Here, we showed that accumulation of intracellular PRPP, produced by consistently active relapse-specific PRPS1 mutants, could promote 5-FU prodrug activation and confers much more sensitivity to 5-FU on PRPS1 mutant Reh cells, prompting that both the mutations in PRPS1 and the expression of PRPS1 are potential biomarkers that can be used to predict tumor sensitivity to 5-FU.
